Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

• Published in: Annals of the rheumatic diseases Vol. 81; no. 11; pp. 1491 - 1503
• Main Authors: Balanescu, Andra-Rodica, Citera, Gustavo, Pascual-Ramos, Virginia, Bhatt, Deepak L, Connell, Carol A, Gold, David, Chen, All-Shine, Sawyerr, Gosford, Shapiro, Andrea B, Pope, Janet E, Schulze-Koops, Hendrik
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and European League Against Rheumatism 01.11.2022; Elsevier Limited; BMJ Publishing Group
• Subjects: Analgesics, Opioid - therapeutic use; antirheumatic agents; Antirheumatic Agents - adverse effects; arthritis, rheumatoid; Arthritis, Rheumatoid - chemically induced; Arthritis, Rheumatoid - drug therapy; C-Reactive Protein; Cardiovascular diseases; Drug dosages; Female; Humans; Infections; Joint diseases; Lung diseases; Lung Diseases - drug therapy; Necrosis; Patients; Piperidines; Pyrimidines; Pyrroles - adverse effects; Rheumatoid Arthritis; Risk factors; Steroids; Surveillance; therapeutics; Tuberculosis; Tumor necrosis factor; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tumor necrosis factor-TNF; Tumors; Canada; United States > US; arthritis, rheumatoid; therapeutics; tumor necrosis factor inhibitors; antirheumatic agents

ObjectivesTo characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance.MethodsIn this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times per day or a tumour necr...